

# Patrick Harris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3781773/publications.pdf>

Version: 2024-02-01

128  
papers

4,539  
citations

186265

28  
h-index

123424

61  
g-index

147  
all docs

147  
docs citations

147  
times ranked

5918  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of Carbapenems vs New Antibiotics for Treatment of Adult Patients With Complicated Urinary Tract Infections: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofaa480.	0.9	7
2	Unexpected benefit of COVID-19 hospital restrictions: Reduction in patients isolating with multidrug resistant organisms after restrictions were lifted. <i>Infection, Disease and Health</i> , 2022, 27, 10-14.	1.1	4
3	The epidemiology of melioidosis in Townsville, Australia. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2022, 116, 328-335.	1.8	6
4	Melioidosis: Laboratory Investigations and Association with Patient Outcomes. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 54-59.	1.4	8
5	Strengths and caveats of identifying resistance genes from whole genome sequencing data. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 533-547.	4.4	7
6	Multiplex Microsphere PCR (mmPCR) Allows Simultaneous Gram Typing, Detection of Fungal DNA, and Antibiotic Resistance Genes. <i>Laboratory Medicine</i> , 2022, 53, 459-464.	1.2	1
7	Comparative evaluation of Panther Fusion and real-time PCR for detection of <i>Burkholderia pseudomallei</i> in spiked human blood. <i>Access Microbiology</i> , 2022, 4, .	0.5	1
8	Activity of temocillin against third-generation cephalosporin-resistant <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> bloodstream isolates from a clinical trial. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlab192.	2.1	4
9	Speed and safety of mass spectrometry for identification of <i>Burkholderia pseudomallei</i> directly from spiked blood cultures. <i>Journal of Medical Microbiology</i> , 2022, 71, .	1.8	0
10	<i>Morganella morganii</i> , an Emerging Cause of Bloodstream Infections. <i>Microbiology Spectrum</i> , 2022, 10, e0056922.	3.0	10
11	Guideline of guidelines: management of recurrent urinary tract infections in women. <i>BJU International</i> , 2022, 130, 11-22.	2.5	32
12	CATHAI: cluster analysis tool for healthcare-associated infections. <i>Bioinformatics Advances</i> , 2022, 2, .	2.4	3
13	Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum $\beta$ -lactamase-producing and non-producing <i>Escherichia coli</i> clinical isolates in a hollow-fibre infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2448-2455.	3.0	3
14	Carriage Duration and Household Transmission of Enterobacterales Producing Extended-Spectrum Beta-Lactamase in the Community: A Systematic Review and Meta-Analysis. <i>Microbial Drug Resistance</i> , 2022, 28, 795-805.	2.0	10
15	Pharmacodynamic evaluation of piperacillin/tazobactam against extended-spectrum $\beta$ -lactamase-producing versus non-producing <i>Escherichia coli</i> in a hollow-fibre infection model. <i>International Journal of Antimicrobial Agents</i> , 2022, , 106623.	2.5	1
16	Clinical <i>Burkholderia pseudomallei</i> isolates from north Queensland carry diverse bimABm genes that are associated with central nervous system disease and are phylogenomically distinct from other Australian strains. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0009482.	3.0	3
17	<i>Achromobacter</i> Species: An Emerging Cause of Community-Onset Bloodstream Infections. <i>Microorganisms</i> , 2022, 10, 1449.	3.6	5
18	Performance of the BioFire Blood Culture Identification 2 panel for the diagnosis of bloodstream infections. <i>Heliyon</i> , 2022, 8, e09983.	3.2	11

#	ARTICLE	IF	CITATIONS
19	Acute Myocardial Infarction and Community-acquired <i>Staphylococcus aureus</i> Bloodstream Infection: An Observational Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e2647-e2655.	5.8	4
20	Completing the Picture—Capturing the Resistome in Antibiotic Clinical Trials. <i>Clinical Infectious Diseases</i> , 2021, 72, e1122-e1129.	5.8	2
21	Beyond the Core Genome: Tracking Plasmids in Outbreaks of Multidrug-resistant Bacteria. <i>Clinical Infectious Diseases</i> , 2021, 72, 421-422.	5.8	15
22	<i>Burkholderia pseudomallei</i> Clinical Isolates Are Highly Susceptible <i>In Vitro</i> to Cefiderocol, a Siderophore Cephalosporin. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	17
23	An update on cefepime and its future role in combination with novel $\beta$ -lactamase inhibitors for MDR Enterobacterales and <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 550-560.	3.0	30
24	Reply to Reza Hosseini and Nielsen. <i>Clinical Infectious Diseases</i> , 2021, 72, e916-e916.	5.8	0
25	Transrectal versus transperineal prostate biopsy under intravenous anaesthesia: a clinical, microbiological and cost analysis of 2048 cases over 11 years at a tertiary institution. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 169-176.	3.9	24
26	OUP accepted manuscript. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab157.	2.1	4
27	Evaluating the economic effects of genomic sequencing of pathogens to prioritise hospital patients competing for isolation beds. <i>Australian Health Review</i> , 2021, 45, 59.	1.1	5
28	Detecting antimicrobial resistance in <i>Escherichia coli</i> using benchtop attenuated total reflectance-Fourier transform infrared spectroscopy and machine learning. <i>Analyst</i> , 2021, 146, 6211-6219.	3.5	6
29	Budget impact analysis of routinely using whole-genomic sequencing of six multidrug-resistant bacterial pathogens in Queensland, Australia. <i>BMJ Open</i> , 2021, 11, e041968.	1.9	28
30	Genomic surveillance, characterization and intervention of a polymicrobial multidrug-resistant outbreak in critical care. <i>Microbial Genomics</i> , 2021, 7, .	2.0	22
31	Diagnosis of melioidosis: the role of molecular techniques. <i>Future Microbiology</i> , 2021, 16, 271-288.	2.0	10
32	Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (MERINO-3): study protocol for a multicentre, open-label randomised non-inferiority trial. <i>Trials</i> , 2021, 22, 301.	1.6	11
33	A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to gram-negative pathogens. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1746-1753.	6.0	5
34	Adverse clinical outcomes associated with infections by Enterobacterales producing ESBL (ESBL-E): a systematic review and meta-analysis. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, .	2.1	13
35	Rapid detection of NDM and VIM carbapenemase encoding genes by recombinase polymerase amplification and lateral flow-based detection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2447-2453.	2.9	12
36	Molecular Epidemiology of Third-Generation-Cephalosporin-Resistant Enterobacteriaceae in Southeast Queensland, Australia. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	9

#	ARTICLE	IF	CITATIONS
37	Laboratory Safety: Handling <i>Burkholderia pseudomallei</i> Isolates without a Biosafety Cabinet. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0042421.	3.9	8
38	New Microbiological Techniques for the Diagnosis of Bacterial Infections and Sepsis in ICU Including Point of Care. <i>Current Infectious Disease Reports</i> , 2021, 23, 12.	3.0	26
39	MicroPIPE: validating an end-to-end workflow for high-quality complete bacterial genome construction. <i>BMC Genomics</i> , 2021, 22, 474.	2.8	25
40	Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC $\beta$ -Lactamase-Producing <i>Enterobacter</i> spp, <i>Citrobacter freundii</i> , <i>Morganella morganii</i> , <i>Providencia</i> spp, or <i>Serratia marcescens</i> : A Pilot Multicenter Randomized Controlled Trial (MERINO-2). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab387.	0.9	42
41	<i>In Vitro</i> Activity of Cefotetan against ESBL-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Bloodstream Isolates from the MERINO Trial. <i>Microbiology Spectrum</i> , 2021, 9, e0022621.	3.0	5
42	Discrepancy between VITEK2 and Etest aminoglycoside susceptibility testing for multidrug-resistant <i>Acinetobacter baumannii</i> . <i>Pathology</i> , 2021, 53, 805-808.	0.6	0
43	PRO: Carbapenems should be used for ALL infections caused by ceftriaxone-resistant Enterobacterales. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab013.	2.1	12
44	An update on cefepime and its future role in combination with novel $\beta$ -lactamase inhibitors for MDR Enterobacterales and <i>Pseudomonas aeruginosa</i> response. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3327-3328.	3.0	2
45	The impact of COVID-19 epidemic phase and changes in mean viral loads: implications for SARS-CoV-2 testing strategies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 102, 115598.	1.8	2
46	Genomic analysis of <i>Elizabethkingia</i> species from aquatic environments: evidence for potential clinical transmission. <i>Current Research in Microbial Sciences</i> , 2021, 3, 100083.	2.3	2
47	Cost-effectiveness analysis of whole-genome sequencing during an outbreak of carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Stewardship &amp; Healthcare Epidemiology</i> , 2021, 1, .	0.5	5
48	Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. <i>Trials</i> , 2021, 22, 889.	1.6	6
49	Modern Clinician-initiated Clinical Trials to Determine Optimal Therapy for Multidrug-resistant Gram-negative Infections. <i>Clinical Infectious Diseases</i> , 2020, 71, 433-439.	5.8	1
50	Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia. <i>Current Opinion in Infectious Diseases</i> , 2020, 33, 78-85.	3.1	23
51	Clinical and Economic Outcomes of Genome Sequencing Availability on Containing a Hospital Outbreak of Resistant <i>Escherichia coli</i> in Australia. <i>Value in Health</i> , 2020, 23, 994-1002.	0.3	10
52	Is Ceftazidime/Avibactam an Option for Serious Infections Due to Extended-Spectrum- $\beta$ -Lactamase- and AmpC-Producing Enterobacterales?: a Systematic Review and Meta-analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	20
53	Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against <i>Pseudomonas aeruginosa</i> in a Dynamic <i>In Vitro</i> Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	7
54	Contamination of SARS-CoV-2 RT-PCR probes at the oligonucleotide manufacturer. <i>Pathology</i> , 2020, 52, 814-816.	0.6	12

#	ARTICLE	IF	CITATIONS
55	<i>Achromobacter</i> Infections and Treatment Options. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	82
56	Antimicrobial Resistance in ESKAPE Pathogens. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	13.6	898
57	Comparative Genomics and Antimicrobial Resistance Profiling of <i>Elizabethkingia</i> Isolates Reveal Nosocomial Transmission and <i>In Vitro</i> Susceptibility to Fluoroquinolones, Tetracyclines, and Trimethoprim-Sulfamethoxazole. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	27
58	Pharmacodynamic evaluation of intermittent versus extended and continuous infusions of piperacillin/tazobactam in a hollow-fibre infection model against <i>Klebsiella pneumoniae</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2633-2640.	3.0	12
59	A hybrid simulation model approach to examine bacterial genome sequencing during a hospital outbreak. <i>BMC Infectious Diseases</i> , 2020, 20, 72.	2.9	16
60	Bacterial Profile, Multi-Drug Resistance and Seasonality Following Lower Limb Orthopaedic Surgery in Tropical and Subtropical Australian Hospitals: An Epidemiological Cohort Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 657.	2.6	6
61	Integrating multiple genomic technologies to investigate an outbreak of carbapenemase-producing <i>Enterobacter hormaechei</i> . <i>Nature Communications</i> , 2020, 11, 466.	12.8	34
62	Genomic Investigation Reveals Contaminated Detergent as the Source of an Extended-Spectrum- $\beta$ -Lactamase-Producing <i>Klebsiella michiganensis</i> Outbreak in a Neonatal Unit. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	37
63	Oral cephalosporin and $\beta$ -lactamase inhibitor combinations for ESBL-producing <i>Enterobacteriaceae</i> urinary tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2384-2393.	3.0	26
64	Genomic analysis of carbapenemase-producing <i>Enterobacteriaceae</i> in Queensland reveals widespread transmission of bla <sub>IMP-4</sub> on an IncHI2 plasmid. <i>Microbial Genomics</i> , 2020, 6, .	2.0	19
65	Evaluation of the SpeedX Carba (beta) multiplex real-time PCR assay for detection of NDM, KPC, OXA-48-like, IMP-4-like and VIM carbapenemase genes. <i>BMC Infectious Diseases</i> , 2019, 19, 571.	2.9	14
66	Modifiable risk factors for multidrug-resistant Gram-negative infection in critically ill burn patients: a systematic review and meta-analysis. <i>ANZ Journal of Surgery</i> , 2019, 89, 1256-1260.	0.7	11
67	Bacterial identification using a SCIEX 5800 TOF/TOF MALDI research instrument and an external database. <i>Journal of Microbiological Methods</i> , 2019, 164, 105685.	1.6	3
68	Antimicrobial treatment challenges in the era of carbapenem resistance. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 413-425.	1.8	50
69	Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2019, 6, .	0.9	13
70	Benzylopenicillin versus flucloxacillin for penicillin-susceptible <i>Staphylococcus aureus</i> bloodstream infections from a large retrospective cohort study. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 491-495.	2.5	20
71	By ZEUS! Can We Use Intravenous Fosfomycin for Complicated Urinary Tract Infections?. <i>Clinical Infectious Diseases</i> , 2019, 69, 2057-2058.	5.8	3
72	Association between higher ambient temperature and orthopaedic infection rates: a systematic review and meta-analysis. <i>ANZ Journal of Surgery</i> , 2019, 89, 1028-1034.	0.7	3

#	ARTICLE	IF	CITATIONS
73	Antibiotics for Ceftriaxone Resistant Gram-Negative Bacterial Bloodstream Infectionsâ€”Reply. JAMA - Journal of the American Medical Association, 2019, 321, 613.	7.4	6
74	Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?. International Journal of Antimicrobial Agents, 2019, 53, 211-224.	2.5	68
75	Quantitative real-time PCR assay for the rapid identification of the intrinsically multidrug-resistant bacterial pathogen <i>Stenotrophomonas maltophilia</i> . Microbial Genomics, 2019, 5, .	2.0	8
76	Whole genome analysis of cephalosporin-resistant <i>Escherichia coli</i> from bloodstream infections in Australia, New Zealand and Singapore: high prevalence of CMY-2 producers and ST131 carrying blaCTX-M-15 and blaCTX-M-27. Journal of Antimicrobial Chemotherapy, 2018, 73, 634-642.	3.0	56
77	The effectiveness of targeted relative to empiric prophylaxis on infectious complications after transrectal ultrasound-guided prostate biopsy: a meta-analysis. World Journal of Urology, 2018, 36, 1007-1017.	2.2	36
78	Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis. World Journal of Urology, 2018, 36, 323-330.	2.2	38
79	Health Risks of Flood Disasters. Clinical Infectious Diseases, 2018, 67, 1450-1454.	5.8	108
80	Copper Ions and Coordination Complexes as Novel Carbapenem Adjuvants. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	31
81	Fosfomycin: what was old is new again. Internal Medicine Journal, 2018, 48, 1425-1429.	0.8	5
82	Discovery of <i>mcr-1</i> -Mediated Colistin Resistance in a Highly Virulent <i>Escherichia coli</i> Lineage. MSphere, 2018, 3, .	2.9	48
83	Infectious complications following transrectal ultrasound-guided prostate biopsy: what additional diagnostic value do blood cultures provide?. Infectious Diseases, 2018, 50, 804-806.	2.8	1
84	Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance. JAMA - Journal of the American Medical Association, 2018, 320, 984.	7.4	538
85	Long-term morbidity and mortality following bloodstream infection: A systematic literature review. Journal of Infection, 2018, 77, 1-8.	3.3	53
86	Risk factors for relapse or persistence of bacteraemia caused by <i>Enterobacter</i> spp.: a caseâ€”control study. Antimicrobial Resistance and Infection Control, 2017, 6, 14.	4.1	26
87	Chlorhexidine gluconate or polyhexamethylene biguanide disc dressing to reduce the incidence of central-line-associated bloodstream infection: a feasibility randomized controlled trial (the CLABSI) Tj ETQq1 1 0.784314 rgBTj Overlo	1.0	1
88	Prostate Biopsy-related Infection: A Systematic Review of Risk Factors, Prevention Strategies, and Management Approaches. Urology, 2017, 104, 11-21.	1.0	92
89	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	2.5	8
90	Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. Clinical Microbiology and Infection, 2017, 23, 533-541.	6.0	58

#	ARTICLE	IF	CITATIONS
91	Melioidosis, Singapore, 2003–2014. <i>Emerging Infectious Diseases</i> , 2017, 24, .	4.3	9
92	Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. <i>PLoS ONE</i> , 2016, 11, e0153696.	2.5	104
93	Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw459.	3.0	57
94	Detection of carbapenemase activity in Enterobacteriaceae using LC-MS/MS in comparison with the neo-rapid CARB kit using direct visual assessment and colorimetry. <i>Journal of Microbiological Methods</i> , 2016, 131, 68-72.	1.6	6
95	Central nervous system nocardiosis in Queensland. <i>Medicine (United States)</i> , 2016, 95, e5255.	1.0	39
96	Carbapenems versus alternative antibiotics for the treatment of bloodstream infections caused by <i>Enterobacter</i> , <i>Citrobacter</i> or <i>Serratia</i> species: a systematic review with meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 296-306.	3.0	62
97	An outbreak of scrub typhus in military personnel despite protocols for antibiotic prophylaxis: doxycycline resistance excluded by a quantitative PCR-based susceptibility assay. <i>Microbes and Infection</i> , 2016, 18, 406-411.	1.9	22
98	Colistin resistance: a major breach in our last line of defence. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 132-133.	9.1	152
99	Antimicrobial susceptibility reporting and treatment selection for AmpC-producing Enterobacteriaceae: what do microbiologists and infectious disease practitioners actually practice?. <i>Pathology</i> , 2015, 47, 386-388.	0.6	10
100	Facing the challenge of multidrug-resistant gram-negative bacilli in Australia. <i>Medical Journal of Australia</i> , 2015, 202, 243-246.	1.7	31
101	Comparable outcomes for $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant <i>Escherichia coli</i> or <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Resistance and Infection Control</i> , 2015, 4, 14.	4.1	50
102	Clinical Management of Infections Caused by Enterobacteriaceae that Express Extended-Spectrum $\beta$ -Lactamase and AmpC Enzymes. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015, 36, 056-073.	2.1	34
103	$\beta$ -lactam and $\beta$ -lactamase inhibitor combinations in the treatment of extended-spectrum $\beta$ -lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 475-485.	9.1	163
104	Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4375-4378.	3.2	24
105	Antiseptic Body Washes for Reducing the Transmission of Methicillin-Resistant <i>Staphylococcus aureus</i> : A Cluster Crossover Study. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv051.	0.9	15
106	Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible <i>Escherichia coli</i> and <i>Klebsiella</i> spp (the MERINO trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 24.	1.6	57
107	<i>Editorial Commentary</i> : The New <i>Acinetobacter</i> Equation: Hypervirulence Plus Antibiotic Resistance Equals Big Trouble: Table 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, 155-156.	5.8	23
108	The emerging threat of multidrug-resistant Gram-negative bacteria in urology. <i>Nature Reviews Urology</i> , 2015, 12, 570-584.	3.8	283

#	ARTICLE	IF	CITATIONS
109	Melioidosis: refining management of a tropical time bomb. <i>Lancet, The</i> , 2014, 383, 762-764.	13.7	15
110	Atypical hand, foot, and mouth disease: eczema coxsackium can also occur in adults. <i>Lancet Infectious Diseases, The</i> , 2014, 14, 1043.	9.1	25
111	Acute Q fever in northern Queensland: variation in incidence related to rainfall and geographical location. <i>Epidemiology and Infection</i> , 2013, 141, 1034-1038.	2.1	14
112	Comparison of Vitek MS (MALDI-TOF) to standard routine identification methods: an advance but no panacea. <i>Pathology</i> , 2012, 44, 583-585.	0.6	13
113	Antibiotic therapy for inducible AmpC $\beta$ -lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides?. <i>International Journal of Antimicrobial Agents</i> , 2012, 40, 297-305.	2.5	102
114	Adhesive tape in the health care setting: another high-risk fomite?. <i>Medical Journal of Australia</i> , 2012, 196, 34-34.	1.7	15
115	Comparative in vitro susceptibility of <i>Burkholderia pseudomallei</i> to doripenem, ertapenem, tigecycline and moxifloxacin. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 547-549.	2.5	18
116	Challenges in the microbiological diagnosis and management of hVISA infections. <i>Pathology</i> , 2011, 43, 357-361.	0.6	6
117	Automated erythrocytapheresis for severe falciparum malaria. <i>Internal Medicine Journal</i> , 2011, 41, 60-63.	0.8	11
118	Bacteraemia caused by beta-haemolytic streptococci in North Queensland: changing trends over a 14-year period. <i>Clinical Microbiology and Infection</i> , 2011, 17, 1216-1222.	6.0	30
119	<i>Coxiella burnetii</i> causing haemophagocytic syndrome: a rare complication of an unusual pathogen. <i>Infection</i> , 2011, 39, 579-582.	4.7	16
120	Evidence of <i>Burkholderia pseudomallei</i> -Specific Immunity in Patient Sera Persistently Nonreactive by the Indirect Hemagglutination Assay. <i>Vaccine Journal</i> , 2011, 18, 1288-1291.	3.1	10
121	Herpes Zoster Meningoencephalitis: Not Only a Disease of the Immunocompromised?. <i>Infection</i> , 2010, 38, 73-75.	4.7	14
122	Another Killer of the Australian Bush: A Rapidly Fatal Meningoencephalitis in a Child. <i>Clinical Infectious Diseases</i> , 2010, 50, 1375-1376.	5.8	5
123	Health Impact Assessment for Urban and Land-use Planning and Policy Development: Lessons from Practice. <i>Planning Practice and Research</i> , 2010, 25, 531-541.	1.7	11
124	Pandemic influenza H1N1 2009 in north Queensland--risk factors for admission in a region with a large indigenous population. <i>Communicable Diseases Intelligence Quarterly Report</i> , 2010, 34, 102-9.	0.5	7
125	Clinical Features That Affect Indirect-Hemagglutination-Assay Responses to <i>Burkholderia pseudomallei</i> . <i>Vaccine Journal</i> , 2009, 16, 924-930.	3.1	34
126	A health impact assessment on the construction phase of a major hospital redevelopment. <i>Australian Health Review</i> , 2008, 32, 509.	1.1	6

#	ARTICLE	IF	CITATIONS
127	Relevance of the pH probe in sleep study analysis in infants. Child: Care, Health and Development, 2004, 30, 337-344.	1.7	17
128	Determining risk factors for symptomatic urinary tract infection following trial of void: A retrospective analysis. Journal of Clinical Urology, 0, , 205141582210998.	0.1	0